Clinical Trial Update: Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing sorafenib plus tegafur-uracil (UFT) versus sorafenib as first-line treatment for advanced hepatocellular carcinoma has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Tegafur-Uracil (tegafur-uracil)

Snippet

Sponsor: Egyptian Society of Liver Cancer | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED